Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

June 30, 2020 09:07 AM EDTUpdated 10:20 AM

Positive Covid-19 vaccine data? New mouse study? OWS inclusion? Yep, but somehow, the usual tidbits from Inovio backfire

You don’t go more than 40 years in biotech without ever getting a product to market unless you can learn the art of writing a …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

TRENDING NOW

FDA picks controversial doctor Vinay Prasad as CBER director, in about-face from Marks

Biotech stocks plunge and industry figures left to wonder after Prasad's FDA appointment

What Vinay Prasad means for CBER, vaccines, drug approvals and more

Even as questions grow over RFK Jr.'s vaccine policy, BioNTech doesn't see ‘near-term’ impact

Novo Nordisk trims growth forecast as GLP-1 compounder ban yet to go live

sponsored

In one of the riskiest industries — Biotech — a surefire way to neutralize some of that risk emerges